Abstract: The present disclosure provides a method for designing a supercritical heat exchanger based on pseudo-phase transition partition. The method mainly includes the following steps: inputting boundary conditions of a heat exchanger; calculating an upper boundary temperature and a lower boundary temperature of a pseudo-phase transition region; calculating a temperature of an inner wall surface of a supercritical fluid; determining an upper boundary temperature of a pseudo-superheated condensation region; and dividing the heat exchanger into four sections on the basis of above three boundary temperatures and inlet and outlet temperatures, and calculating the section size and the total size of the heat exchanger. According to the method, the automatic partition determination of single-phase cooling and pseudo-superheated condensation in a supercritical air cooler can be realized, requiring no division of the heat exchanger according to equal enthalpy change or equal length, and the calculation is rapid and accurate.

Abstract: A deflector for a condenser, the condenser has an inlet communicated with exhaust pipes of a compressor, and the deflector is provided at the inlet, the deflector includes: a flow guiding structure having a first tube section and a second tube section of increasing diameter, the second tube section being positioned below the first tube section and extending into the condenser when mounted in place; and a support assembly for fixing the flow guiding structure at the inlet, at least a part of the refrigerant gas flow flows through the interior of the first tube section, and at least another part of the refrigerant gas flow flows through the outer side of the first tube section.

Abstract: Provided is a method for removing arsenic from copper smelting soot and comprehensive recovery of valuable metals. According to the method, a metal leaching synergist is prepared through thiol-ene click chemical reaction, which is capable of reacting more effectively with arsenic and metal impurities in the copper smelting soot due to its special chemical structure, thereby improving leaching efficiency; and the cage-like structure of the polysilsesquioxane provides excellent chemical stability, the removal rate of harmful substances in the copper smelting soot can be increased by using the synergist, environmental pollution is reduced, meanwhile, the recovery rate of metal resources is increased, and the requirements of green chemistry and sustainable development are met. The present disclosure realizes the centralized management of As and also realizes the step-by-step recovery of valuable metals such as Cu, Zn, Pb, Bi, and In.

Abstract: A deflector for a condenser. The condenser has an inlet in communication with a compressor, and a deflector for guiding a refrigerant gas flow from the compressor is arranged in the condenser and at a position close to the inlet. The deflector is provided with a deflecting structure projecting toward the inlet, and the deflecting structure is configured as impermeable to the refrigerant gas flow.

Abstract: The invention discloses a use of a mulberry (Morus alba L.) extract, including a method for treating ulcerative colitis, a method for preventing ulcerative colitis, and a method for reduction in Disease Activity Index, DAI. The use is application of a mulberry extract to the preparation of a product for treating and/or preventing ulcerative colitis. The invention experimentally demonstrated that positive drug group, SZ-A-1, SZ-A-2, SZ-A-3, SZ-A-4 and SZ-A-5 (pretreatment) could each significantly inhibit colonic atrophy in UC model mice, and the effects in SZ-A-2, SZ-A-3 and SZ-A-4 groups are comparable to that in positive drug group, with SZ-A-5 (pretreatment) achieving a superior effect to the positive drug. The mulberry extract of the invention, as a component derived from natural plants, has unique advantages of small toxic and side effects, mild and lasting actions etc.

Abstract: A display panel comprises a hole, a transition region, and an image display region. A display layer of the display panel is located on a side of a substrate and includes a first cathode portion. The display panel further includes an isolation column located in the transition region, and a first film layer is in contact with the isolation column. The isolation column includes an insulation isolation portion. A part of a side wall of the insulation isolation portion is recessed toward an inside of the insulation isolation portion to form a groove. A first surface of a side of the insulation isolation portion is away from the substrate. The first cathode portion extending on the first film layer is separated at the groove from the first cathode portion extending on the first surface.

Abstract: An electrochromic apparatus includes a first glass, a first adhesive layer disposed on the first glass, a second glass, a second adhesive layer disposed on the second glass, a solid-state electrochromic device (ECD) interposed between the first adhesive layer and the second adhesive layer, and a sealant disposed at edges of the first glass and the second glass to seal the ECD. The first adhesive layer and the second adhesive layer are disposed between the first glass and the second glass. The first adhesive layer and the second adhesive layer are optically transparent. Edges of the adhesive layers are flush with or beyond edges of the ECD. The sealant is adhesive and waterproof.

Abstract: An electrochromic device includes a first flexible substrate, a first transparent electrode disposed on the first flexible substrate, an electrochromic layer disposed on the first transparent electrode, and a solid electrolyte layer disposed on the electrochromic layer. The solid electrolyte layer contains less than 20 wt % of neutral small organic molecules having a molecular weight of 3000 or less. The electrochromic device further includes an ion storage layer disposed on the solid electrolyte layer, a second transparent electrode disposed on the ion storage layer, and a second flexible substrate disposed on the second transparent electrode.

Abstract: An electrochromic apparatus includes a first glass, a first adhesive layer disposed on the first glass, a second glass, a second adhesive layer disposed on the second glass, a solid-state electrochromic device (ECD) interposed between the first adhesive layer and the second adhesive layer, and a sealant disposed at edges of the first glass and the second glass to seal the ECD. The first adhesive layer and the second adhesive layer are disposed between the first glass and the second glass. The first adhesive layer and the second adhesive layer are optically transparent. Edges of the adhesive layers are flush with or beyond edges of the ECD. The sealant is adhesive and waterproof.

Abstract: An electrochromic device includes a first flexible substrate, a first transparent electrode disposed on the first flexible substrate, an electrochromic layer disposed on the first transparent electrode, and a solid electrolyte layer disposed on the electrochromic layer. The solid electrolyte layer contains less than 20 wt % of neutral small organic molecules having a molecular weight of 3000 or less. The electrochromic device further includes an ion storage layer disposed on the solid electrolyte layer, a second transparent electrode disposed on the ion storage layer, and a second flexible substrate disposed on the second transparent electrode.

Abstract: Adipose tissue has proven to serve as an abundant, accessible, and rich source of endothelial or vascular endothelial cells suitable for tissue engineering. We describe a detailed method for the isolation and purification of endothelial cells using purified enzymes and antibody-based selection. The cells can be obtained from liposuction procedures and used in vascular grafts.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: The present invention provides compositions comprising isolated elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: Adipose tissue has proven to serve as an abundant, accessible, and rich source of endothelial or vascular endothelial cells suitable for tissue engineering. We describe a detailed method for the isolation and purification of endothelial cells using purified enzymes and antibody-based selection. The cells can be obtained from liposuction procedures and used in vascular grafts.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

Abstract: The invention relates to a Neutrokine-alpha protein in crystalline form, a method of preparing a Neutrokine-alpha protein in crystalline form, and methods of using a Neutrokine-alpha protein in crystalline form. In particular, the three-dimensional structure of a Neutrokine-alpha protein in crystalline form is used to design molecules that have biological activity. The methods are useful for designing compounds that bind to a Neutrokine-alpha protein, inhibit a Neutrokine-alpha protein, mimic a Neutrokine-alpha protein, and/or enhance the activity of a Neutrokine-alpha protein. The three-dimensional structure of a Neutrokine-alpha protein, as provided herein, is also used to determine the three-dimensional of other Neutrokine-alpha proteins and homologues thereof.

Abstract: The invention relates to methods of isolating differentiable fetal-derived cells from various tissues of the placenta. Specifically, some of the methods of the present invention relate to isolating differentiable amnion-derived cells, while other methods of the present invention relate to isolating differentiable chorion-derived cells. The present invention also relates to methods of inducing these isolated differentiable amnion-derived and differentiable chorion-derived cells to at least partially differentiate. The present invention also relates to methods of treating insulin deficiencies in a subject by administering these differentiable amnion-derived cells and/or differentiable chorion-derived cells to subjects in need thereof.